Search
belzutifan (Welireg)
Indications:
- cancers associated with von Hippel-Lindau disease
- renal cell carcinomas
- CNS hemangioblastomas
- pancreatic neuroendocrine tumors
Dosage:
- once daily continued until disease progression
Pharmacokinetics:
- median time to treatment response is 8.2 months
Adverse effects:
- anemia (90%), an on-target effect of the drug
- fatigue (66%), headache (41%), dizziness (39%), nausea (34%), dyspnea (23%), hypertension (> 8%)
Mechanism of action:
- targets hypoxia-inducible factor 2-alpha
General
antineoplastic agent (chemotherapeutic agent)
References
- Bankhead C
FDA Approves First Drug for Von Hippel-Lindau-Associated Tumors.
Objective response or stable disease in 100% of renal cell carcinomas.
MedPage Today August 13, 2021
https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/94034